Biocon Q1 Core Operations Shine

  Published 10 months ago

Biocon’s Q1 FY26 saw core EBITDA grow 11% YoY, with strong biosimilars and CRDMO growth offsetting one-time gains.

  • Biosimilars revenue jumped 18% YoY to Rs 2,458 crore, fueled by strong demand and new product launches globally.
  • CRDMO business grew 11% in revenue and 19% in EBITDA, driven by pilot programs converting into long-term contracts.
  • Operating revenue rose 15% YoY to Rs 3,942 crore, reflecting broad-based growth across biosimilars, generics, and research services.

You might like these

Oil Stocks Rise as Crude Prices Drop

Auto Retail: May '25, Mixed Signals

Ola Electric Ferrite Motor Certified

Citi Cuts 3,500 Tech Jobs in China

India's Services Trade: April 2025 Update

Premier Energies Stock Surges Amid Block Deal Divestment

India's Risky $3.5B Private Credit Deal

News that matters the most ⚡